Innate Pharma
Update in progressIPHA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Innate Pharma S.A. is a Marseille‑based biotechnology company developing cancer immunotherapies for France and worldwide. Its portfolio includes Lacutamab (IPH4102), an anti‑KIR3DL2 antibody in Phase II for cutaneous and peripheral T‑cell lymphomas and Sézary syndrome; Monalizumab, a checkpoint inhibitor in Phase III for advanced solid tumors; IPH5201, IPH5301, IPH6401, IPH6101, and IPH62. Preclinical programs include IPH43, IPH45, and IPH67. Partners include AstraZeneca, Novo Nordisk, Sanofi, Orega Biotech, and MedImmune.
Company score
- Sentiment
- 0.20
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.12
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationFrance
- CEOMr. Jonathan E. Dickinson B.Sc., M.B.A.
- Founded1999
- Employees164
- Websitewww.innate-pharma.com
Identifiers
- ISINUS45781K2042
- FIGIBBG009ZCBVG7
- CUSIP45781K204